SCHEMBL5459901

SCHEMBL5459901

O=C(c1ccc2[nH]c3c(c2c1)CCCC3NC1CCCCC1)N1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RB1 P06400 5/20 0.53
PARP1 P09874 5/20 0.49
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
ALOX15 P16050 2/20 0.44
BRD3 Q15059 1/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GLA P06280 1/20 0.43
CNR1 P21554 1/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CNR2 P34972 1/20 0.42
KDM4E B2RXH2 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461711 0.92 RB1 (0.57) RB1PARP1MAPTSMN1; SMN2ALOX15
SCHEMBL5445797 0.92 RB1 (0.57) RB1PARP1MAPTSMN1; SMN2ALOX15
SCHEMBL5456645 0.89 RB1 (0.53) RB1PARP1MAPTSMN1; SMN2ALOX15
SCHEMBL5463493 0.83 PARP1 (0.55) RB1PARP1SMN1; SMN2MAPK1MEN1
SCHEMBL5454070 0.83 RB1 (0.63) RB1MAPTSMN1; SMN2ALOX15BRD3
SCHEMBL5458972 0.82 PARP1 (0.52) RB1PARP1MAPTSMN1; SMN2KMT2A
SCHEMBL5467992 0.82 RB1 (0.62) RB1MAPTSMN1; SMN2ALOX15BRD3
SCHEMBL5449883 0.81 RB1 (0.61) RB1MAPTSMN1; SMN2ALOX15BRD3
SCHEMBL5449868 0.80 RB1 (0.60) RB1PARP1MAPTSMN1; SMN2ALOX15
SCHEMBL5459696 0.80 RB1 (0.60) RB1MAPTSMN1; SMN2ALOX15BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 RB1 1821/4885PARP1 709/4885MAPT 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.